Fujimoto M, Sato S, Ihn H, Takehara K
Department of Dermatology, Faculty of Medicine, University of Tokyo, Japan.
Arch Dermatol Res. 1995;287(6):581-5. doi: 10.1007/BF00374080.
We determined the presence of antibodies to the heat-shock protein hsp73 (anti-hsp73) in 57 serum samples from patients with localized scleroderma using an enzyme-linked immunosorbent assay (ELISA). In addition, 30 samples from healthy individuals, 30 from patients with systemic lupus erythematosus (SLE) and 32 from patients with systemic sclerosis were assessed. IgG and/or IgM anti-hsp73 antibodies were detected in 33% (19/57) of the patients with localized scleroderma. Among the three subtypes of localized scleroderma, generalized morphoea showed the highest incidence of anti-hsp73 antibodies (40%, 6/15). IgG and/or IgM anti-hsp73 antibodies were also detected in 9/30 samples (30%) from patients with SLE and in 13/32 samples (41%) from patients with systemic sclerosis, while the samples from the healthy controls were all negative for anti-hsp73. By immunoblotting, specific binding of antibodies to hsp73 was confirmed with representative serum samples that were positive for anti-hsp73 in the ELISA. Our findings indicate that the presence of anti-hsp73 is an additional immunological abnormality in localized scleroderma.
我们采用酶联免疫吸附测定（ELISA）法，检测了57例局限性硬皮病患者血清样本中热休克蛋白hsp73抗体（抗hsp73）的存在情况。此外，还评估了30例健康个体、30例系统性红斑狼疮（SLE）患者及32例系统性硬化症患者的样本。在局限性硬皮病患者中，33%（19/57）检测到IgG和/或IgM抗hsp73抗体。在局限性硬皮病的三种亚型中，泛发性硬斑病抗hsp73抗体的发生率最高（40%，6/15）。SLE患者的30份样本中有9份（30%）、系统性硬化症患者的32份样本中有13份（41%）也检测到IgG和/或IgM抗hsp73抗体，而健康对照样本的抗hsp73检测均为阴性。通过免疫印迹法，用ELISA检测抗hsp73呈阳性的代表性血清样本，证实了抗体与hsp73的特异性结合。我们的研究结果表明，抗hsp73的存在是局限性硬皮病中一种额外的免疫异常情况。
